Receptos radiant on top-line data for Gilenya rival
This article was originally published in Scrip
Receptos jumped 32% in after-hours trading on 9 June after the San Diego-based company said its sphingosine-1-phosphate receptor 1 (S1P1) agonist RPC1063 met the primary endpoint of reduction in MRI brain lesion activity for multiple sclerosis patients enrolled in the Phase II portion of the Phase II/III RADIANCE clinical trial.
You may also be interested in...
Celgene's ozanimod successfully cleared its first Phase III hurdle in multiple sclerosis, but safety will be the S1P receptor modulator's differentiating factor in results presented later this year, with additional value coming from ulcerative colitis and Crohn's disease in the coming years.
Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.
Janux reported early clinical trial data for its lead asset JANX007 that may show differentiated efficacy in the crowded PSMA space and for an EGFR agent with lung and kidney tumor shrinkage.